Varda Space Industries raises $187M Series C to scale space-manufactured pharmaceuticals and biologics lab

Summary

Varda Space Industries has closed a $187 million Series C, with proceeds directed primarily toward scaling its biologics lab in El Segundo, California and increasing launch cadence. The company, led by Will Bruey, has already signed a lease on a second facility nearby, with pharmaceutical equipment installed and operational.

The Core Business Case

Varda's thesis is that microgravity functions as a manufacturing variable the pharmaceutical industry cannot replicate on Earth. Removing gravity slows crystal growth, increases purity, and improves particle size distribution — all factors that affect how a drug is delivered and absorbed in the body. The company frames itself not as a space company but as a formulation development company that uses microgravity as an input, analogous to temperature control in conventional chemistry.

The practical implication is a potential shift in drug delivery formats. Many injectable biologics exist as injections only because the underlying chemistry cannot produce a stable pill or inhalable form at Earth gravity. Varda argues microgravity manufacturing opens new formulation pathways that could change that.

Capacity and Economics Today

Each capsule currently carries roughly 20 kilograms of drug material. At current cadence of approximately four flights per year, each run costs a few million dollars. Bruey's near-term commercial model prioritizes two applications: using single flights to isolate gravity as a variable for R&D insight, and producing polymorph seed crystals in orbit that can then be used to grow larger crystal batches on the ground — a model he compares to a sourdough starter.

Longer term, as costs fall toward thousands of dollars per run and cadence moves toward daily flights, full-dose manufacturing in orbit becomes the target.

Re-entry Infrastructure

Varda currently lands capsules in Australia, which operates a private commercial re-entry range. All U.S. ranges within the 48 contiguous states are designated for military use, making commercial scheduling subordinate to DoD priorities. Bruey confirms that private commercial spaceports are legally permissible in the U.S. — Spaceport America adjacent to White Sands Missile Range is the cited example — but demand has not historically justified the real estate investment. As landing precision improves and required land footprints shrink, Varda expects to expand re-entry sites globally.

An earlier regulatory setback, widely reported as an FAA dispute, was in practice a scheduling conflict at the Utah Test and Training Range. When Varda lost its range slot to higher-priority military work, it automatically lost the associated FAA re-entry license, since the license requires a confirmed range. The resolution was rescheduling further in advance, rerunning atmospheric analysis, and allowing the FAA time to reissue the license. Bruey notes the episode reflected a regulatory gap — no established coordination process existed between the range and the FAA for a commercial re-entry with drugs on board — one Varda effectively had to pioneer.

Talent and Expansion

Bruey acknowledges that AI is drawing software engineering talent away from aerospace, but frames it as a self-selecting filter. Varda is hiring across multiple disciplines and prioritizes mission-driven candidates over those chasing category trends. The company is not pursuing AI-native spacecraft systems by design.

Space-Based Data Centers

On the question of orbital data centers, Bruey is skeptical of the broad thesis but identifies one legitimate use case: latency reduction for applications running over satellite networks like Starlink. By co-locating compute in orbit, a signal avoids the ground-to-satellite-to-ground round trip. He frames this as a form of edge computing — viable for narrow, latency-sensitive workloads, but not a general-purpose argument for moving data infrastructure to space.